VBLT - VBL Therapeutics nabs another European patent covering MOSPD2 for treating cancer

VBL Therapeutics (VBLT) has announced that the European Patent Office has granted patent (no. 3328401) covering the company's investigational anti-MOSPD2 (motile sperm domain-containing protein 2) monoclonal antibodies to treat a wide range of cancers, including solid tumors and hematological cancers.The patent will expire in July 2036.Previously on Oct 12, VBLT secured European patent for anti-MOSPD2 antibodies to treat inflammatory and autoimmune conditions.

For further details see:

VBL Therapeutics nabs another European patent covering MOSPD2 for treating cancer